GSK Establishes Oncology Consortium With An Eye On Combinations
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has aligned with six leading cancer centers to study investigational cancer drugs, with the ambition of advancing novel combinations, including both targeted therapies and immunotherapies.